Glucotrack (GCTK) Net Income towards Common Stockholders (2010 - 2025)

Glucotrack has disclosed Net Income towards Common Stockholders across 15 years of filings, most recently posting -$3.5 million for Q4 2025.

• Quarterly Net Income towards Common Stockholders rose 9.52% year-over-year to -$3.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$16.1 million (down 10.57% YoY) and the FY2025 annual result came in at -$16.1 million, down 10.61% from the prior year.
• Net Income towards Common Stockholders rose to -$3.5 million in Q4 2025, from -$4.3 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $2.4 million in Q4 2023 and troughed at -$4.8 million in Q2 2025.
• A 5-year average of -$1.4 million and a median of -$1.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 229.1% — and 2024, when it slumped 321.12%.
• Tracing GCTK's Net Income towards Common Stockholders over 5 years: stood at -$1.5 million in 2021, then soared by 185.57% to $1.3 million in 2022, then surged by 87.41% to $2.4 million in 2023, then sank by 259.78% to -$3.9 million in 2024, then rose by 9.52% to -$3.5 million in 2025.
• Business Quant data shows GCTK's Net Income towards Common Stockholders at -$3.5 million in Q4 2025, -$4.3 million in Q3 2025, and -$4.8 million in Q2 2025.